US1140822099 - Common Stock
NASDAQ:ERNA (1/30/2023, 7:00:02 PM)-0.06 (-1.24%)
GICS Sector | Health Care | ||
GICS Industry | Biotechnology |
Valuation | Growth | ||
Profitability | Health | ||
Dividend |
Earnings (Last) | 11-14 2022-11-14/amc | Earnings (Next) | N/A N/A |
Ins Owners | 18.92% | Inst Owners | N/A |
Market Cap | 14.06M | Shares | 2.94M |
PE | N/A | Fwd PE | N/A |
Dividend Yield | N/A | Analysts | 43.33 |
IPO | 08-29 1991-08-29 |
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Eterna Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts and currently employs 10 full-time employees. Eterna Therapeutics Inc. is a biopharmaceutical company. The firm is focused on developing advanced therapies using Messenger RNA (mRNA) cell engineering technology. The firm is engaged in developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its product pipeline is based on patented foundational mRNA cell engineering technology and offers multiple clinical applications with future sub-licensing and partnering opportunities. The company formulates mRNA using lipid nanoparticle (LNP) technology. The ToRNAdo delivery system surrounds and protects the mRNA cargo, enabling delivery into human cells. The firm has licensed a portfolio of over 100 patents covering key cell engineering technologies, including therapeutic gene editing in clinical development. The company has multiple cell and gene-editing therapies in preclinical development for various indications.
ETERNA THERAPEUTICS INC
1035 Cambridge Street, Suite 18A
Cambridge MASSACHUSETTS
P: 12125821199.0
Employees: 10
Website: https://eternatx.com/
Roger Sidhu, chief medical officer at Eterna Therapeutics (ERNA), is resigning effective Jan. 31.
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company...
SAN DIEGO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using...
SAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using...
It's time for another look at the biggest pre-market stock movers as we check out what's happening with shares on Tuesday morning!
Here you can normally see the latest stock twits on ERNA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: